#USA #New York #Securities Fraud #Soleno Therapeutics #DCCR Safety

Investor Alert: Class Action Lawsuit Against Soleno Therapeutics

On April 30, 2026, news broke concerning a securities fraud lawsuit against Soleno Therapeutics, Inc. (NASDAQ: SLNO), prompting a call to action for investors who may have suffered losses. The alleged misconduct revolves around misrepresentations regarding the safety of Soleno's drug, VYKAT XR, specifically in relation to its FDA approval and subsequent marketing claims.

Background on Soleno's DCCR Product

Soleno's primary product, VYKAT XR, received approval from the FDA on March 26, 2025, specifically aimed at treating hyperphagia in individuals diagnosed with Prader-Willi syndrome. Initially marketed as having a well-established safety profile, the claims quickly drew scrutiny. Reports had emerged suggesting that the company might have downplayed serious side effects, such as fluid retention, pre-diabetes, and potential heart failure that were observed in clinical trials.

Timeline of Allegations

The timeline highlights a series of statements made by Soleno's executives from the time of FDA approval until November 4, 2025. Here’s a brief overview:

• - March 26, 2025: Following the FDA approval, Soleno's representatives assured stakeholders of the drug’s safety, claiming that it lacked major warnings or contraindications.
• - May 7, 2025: The company touted its Q1 results, suggesting that investor interest was at a high and insinuating that the company was positioned for sustained momentum, despite the ongoing risks associated with VYKAT XR.
• - June 10, 2025: During a presentation at a prestigious healthcare conference, statements were made downplaying severe adverse events and portraying the drug as typically associated with mild, self-limiting side effects.
• - August 6, 2025: A follow-up report proclaimed that there were no new safety signals and lower discontinuation rates compared to earlier trials, reinforcing the previous assurances given to the public and investors.
• - August 15, 2025: A detailed report from Scorpion Capital contradicted these claims, indicating significant safety concerns and caution from clinical trial investigators.

These developments have raised serious questions concerning whether the executives of Soleno Therapeutics adequately informed investors about the real risks associated with their product.

Legal Implications

The securities class action suit posits that between March 26 and November 4, 2025, Soleno failed to disclose critical safety information, contravening their obligations to investors. Investors who purchased SLNO securities during this period may seek redress for the financial damage they incurred due to these alleged misrepresentations.

How to Get Involved

For those who believe they may be eligible to be a lead plaintiff, the deadline for submitting claims is approaching on May 5, 2026. Interested parties are encouraged to contact Joseph E. Levi, Esq., via email or phone to discuss potential involvement in the class action.

Conclusion

The situation surrounding Soleno Therapeutics serves as a stark reminder of the importance of transparency and accountability in the pharmaceutical industry. As this story develops, investors will be keeping a close eye on how the legal proceedings unfold and what implications they may have on the future of Soleno Therapeutics. Investors are urged to stay informed and consider their options in light of these serious allegations.